[
    [
        {
            "time": "2021-07-19",
            "orginal_text": "A股资金流向（7月19日）：资金避高就低，医药、白酒龙头重获资金青睐",
            "features": {
                "keywords": [
                    "医药",
                    "白酒",
                    "资金流向",
                    "避高就低"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股资金流向（7月19日）：资金避高就低，医药、白酒龙头重获资金青睐",
            "scores": {
                "News_content": "A股资金流向（7月19日）：资金避高就低，医药、白酒龙头重获资金青睐",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "北向资金今日净买入近44亿元，持续加仓白酒、医药股",
            "features": {
                "keywords": [
                    "北向资金",
                    "净买入",
                    "白酒",
                    "医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北向资金今日净买入近44亿元，持续加仓白酒、医药股",
            "scores": {
                "News_content": "北向资金今日净买入近44亿元，持续加仓白酒、医药股",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "艾德证券期货：复星医药股价创历史新高，“复必泰”有望加速落地？",
            "features": {
                "keywords": [
                    "复星医药",
                    "股价新高",
                    "复必泰",
                    "加速落地"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "艾德证券期货：复星医药股价创历史新高，“复必泰”有望加速落地？",
            "scores": {
                "News_content": "艾德证券期货：复星医药股价创历史新高，“复必泰”有望加速落地？",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "郭广昌继续重仓海南，400亿欲将海航收入囊中？",
            "features": {
                "keywords": [
                    "郭广昌",
                    "重仓海南",
                    "海航",
                    "400亿"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "航空",
                    "地产"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "郭广昌继续重仓海南，400亿欲将海航收入囊中？",
            "scores": {
                "News_content": "郭广昌继续重仓海南，400亿欲将海航收入囊中？",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "李浩德：复星医药近期五大利好盘点",
            "features": {
                "keywords": [
                    "复星医药",
                    "利好",
                    "盘点"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "李浩德：复星医药近期五大利好盘点",
            "scores": {
                "News_content": "李浩德：复星医药近期五大利好盘点",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "医药行业2021年中期投资策略：创新为行业发展主旋律 聚焦相关高景气、高尖端细分领域",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "创新",
                    "高景气",
                    "高尖端"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "医药行业2021年中期投资策略：创新为行业发展主旋律 聚焦相关高景气、高尖端细分领域",
            "scores": {
                "News_content": "医药行业2021年中期投资策略：创新为行业发展主旋律 聚焦相关高景气、高尖端细分领域",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "复星医药董事长兼CEO吴以芳入选《福布斯2021中国最佳CEO榜》",
            "features": {
                "keywords": [
                    "复星医药",
                    "吴以芳",
                    "福布斯",
                    "最佳CEO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "复星医药董事长兼CEO吴以芳入选《福布斯2021中国最佳CEO榜》",
            "scores": {
                "News_content": "复星医药董事长兼CEO吴以芳入选《福布斯2021中国最佳CEO榜》",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "【异动股】复星医药(02196.HK)涨4.1%",
            "features": {
                "keywords": [
                    "复星医药",
                    "异动股",
                    "涨4.1%"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【异动股】复星医药(02196.HK)涨4.1%",
            "scores": {
                "News_content": "【异动股】复星医药(02196.HK)涨4.1%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-19",
            "orginal_text": "康泰生物布局mRNA人用传染病疫苗项目",
            "features": {
                "keywords": [
                    "康泰生物",
                    "mRNA",
                    "疫苗",
                    "项目"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "康泰生物布局mRNA人用传染病疫苗项目",
            "scores": {
                "News_content": "康泰生物布局mRNA人用传染病疫苗项目",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]